Allogene Therapeutics (ALLO) Capital Expenditures (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Capital Expenditures data on file, last reported at $9000.0 in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures changed N/A year-over-year to $9000.0; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (up 145.84% YoY), and the FY2025 full-year result was $1.3 million, up 130.15% from the prior year.
• Capital Expenditures slipped to $9000.0 in Q1 2026, from $102000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $2.0 million in Q4 2022 to a low of -$4.7 million in Q4 2024.
• A 5-year average of $229125.0 and a median of $422500.0 in 2022 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures surged 673.91% in 2022 and tumbled 4030.0% in 2024, its largest moves.
• Tracing ALLO's Capital Expenditures over 5 years: stood at $2.0 million in 2022, then sank by 93.94% to $120000.0 in 2023, then plunged by 4030.0% to -$4.7 million in 2024, then jumped by 102.16% to $102000.0 in 2025, then slumped by 91.18% to $9000.0 in 2026.
• Business Quant data shows ALLO's Capital Expenditures at $9000.0 in Q1 2026, $102000.0 in Q4 2025, and $973000.0 in Q3 2025.